Refeyn has announced an expansion in the global use of its mass photometry technology among contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). The company has introduced a new webpage to highlight how these organizations are using mass photometry to improve process development and manufacturing workflows. The site also offers an interactive tool for researchers seeking to connect with CROs and CDMOs that use this technology.
Mass photometry, which was launched eight years ago, is being adopted rapidly due to increased demand for quick, reliable, and cost-effective analytics in protein and mRNA characterization, antibody development, and viral vector analysis. The technology is now referenced in nearly 1,500 scientific publications and is utilized by 90% of leading biopharmaceutical companies. It features GMP-compliant software for AAV analytics and has received recognition from regulatory agencies such as the US Pharmacopeia, China's NIFDC, and the British Pharmacopeia.
According to Refeyn, "Leading CROs and CDMOs use mass photometry to deliver rapid, label-free insights into critical quality attributes – AAV capsid purity (full/empty/partial ratios), mRNA integrity and purity- and emerging antibody modalities. This enables clients to make earlier, better-informed development decisions while reducing sample consumption and turnaround times, tackling analytical challenges that are difficult with traditional methods."
The company states that CROs and CDMOs can collaborate with Refeyn to enhance their analytical capabilities in response to growing industry needs for faster data delivery. Biopharma teams can also access mass photometry through Refeyn’s expanding network of partners.
